JP7574222B2 - ピーナツアレルギー患者の生活の質を改善するための方法 - Google Patents

ピーナツアレルギー患者の生活の質を改善するための方法 Download PDF

Info

Publication number
JP7574222B2
JP7574222B2 JP2021566106A JP2021566106A JP7574222B2 JP 7574222 B2 JP7574222 B2 JP 7574222B2 JP 2021566106 A JP2021566106 A JP 2021566106A JP 2021566106 A JP2021566106 A JP 2021566106A JP 7574222 B2 JP7574222 B2 JP 7574222B2
Authority
JP
Japan
Prior art keywords
peanut
oral immunotherapy
period
patient
life
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021566106A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532547A5 (https=
JP2022532547A (ja
Inventor
クリスティーン バーチウッド，
Original Assignee
ソシエテ・デ・プロデュイ・ネスレ・エス・アー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソシエテ・デ・プロデュイ・ネスレ・エス・アー filed Critical ソシエテ・デ・プロデュイ・ネスレ・エス・アー
Publication of JP2022532547A publication Critical patent/JP2022532547A/ja
Publication of JP2022532547A5 publication Critical patent/JP2022532547A5/ja
Application granted granted Critical
Publication of JP7574222B2 publication Critical patent/JP7574222B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2021566106A 2019-05-10 2020-05-08 ピーナツアレルギー患者の生活の質を改善するための方法 Active JP7574222B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962846481P 2019-05-10 2019-05-10
US62/846,481 2019-05-10
US201962855384P 2019-05-31 2019-05-31
US62/855,384 2019-05-31
US202062967948P 2020-01-30 2020-01-30
US62/967,948 2020-01-30
PCT/US2020/032179 WO2020231843A1 (en) 2019-05-10 2020-05-08 Methods for improving the quality of life of a patient with a peanut allergy

Publications (3)

Publication Number Publication Date
JP2022532547A JP2022532547A (ja) 2022-07-15
JP2022532547A5 JP2022532547A5 (https=) 2023-05-11
JP7574222B2 true JP7574222B2 (ja) 2024-10-28

Family

ID=73289227

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021566106A Active JP7574222B2 (ja) 2019-05-10 2020-05-08 ピーナツアレルギー患者の生活の質を改善するための方法

Country Status (7)

Country Link
US (2) US11229673B2 (https=)
EP (1) EP3965815A4 (https=)
JP (1) JP7574222B2 (https=)
CN (1) CN113966229A (https=)
AU (1) AU2020276213A1 (https=)
CA (1) CA3137295A1 (https=)
WO (1) WO2020231843A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
US12433945B2 (en) 2018-08-16 2025-10-07 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
US12226448B2 (en) 2018-12-20 2025-02-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy dosing schedule for missed doses
WO2022003604A1 (en) 2020-07-01 2022-01-06 Société des Produits Nestlé S. A. Determining medical staffing for oral immunotherapy
KR20230148769A (ko) 2022-04-15 2023-10-25 사회복지법인 삼성생명공익재단 경구면역요법을 이용한 식품알레르기 치료서비스 제공방법, 이를 구현하기 위한 기록매체에 저장된 컴퓨터 프로그램 및 시스템

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509606A (ja) 2011-03-17 2014-04-21 ケンブリッジ エンタープライズ リミティッド ピーナッツアレルギーの治療
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
WO2019089978A1 (en) 2017-11-02 2019-05-09 Aimmune Therapeutics, Inc. Methods of oral immunotherapy

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3809767A (en) 1969-05-12 1974-05-07 Griffith Laboratories Methods of making vegetable protein concentrates
AU1589492A (en) 1991-03-01 1992-10-06 Warner-Lambert Company Starch-based controlled release compositions
US20120164306A1 (en) 1993-08-03 2012-06-28 Girsh Leonard S Process for preparing hypoallergenic and reduced fat foods
JP3445593B2 (ja) 1994-09-10 2003-09-08 株式会社林原生物化学研究所 ペプチドとその用途
AU2065801A (en) 1999-12-06 2001-06-12 Panacea Pharmaceuticals, Llc Passive desensitization
AU1951001A (en) 2000-04-06 2001-09-17 Panacea Pharm Llc Microbial delivery system
WO2004047793A1 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
EP1599185A1 (en) 2003-02-28 2005-11-30 Alk-Abello A/S Dosage form having a saccharide matrix
EP1734975B1 (en) 2004-03-19 2015-06-10 Herbs Spring, LLC Herbal therapy for the treatment of food allergy
WO2005100995A2 (en) 2004-04-06 2005-10-27 Mount Sinai School Of Medicine Methods of determining allergen response using microarray imminoassay techinques
BRPI0520821A2 (pt) 2005-12-28 2009-06-30 Teva Pharma formulações farmacêuticas de fenofibrato com biodisponibilidade melhorada
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
HRP20200284T1 (hr) 2008-10-02 2020-07-10 Salix Pharmaceuticals, Ltd. Postupci liječenja hepatičke encefalopatije
BRPI0921507A2 (pt) 2008-11-19 2016-01-19 Avantor Performance Mat Inc composição, método de preparação de um excipiente, comprimido farmacêutico e método de preparação do mesmo
US8399519B2 (en) 2008-12-19 2013-03-19 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
EP2364690A1 (en) 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Orally administrable pharmaceutical pellet of epidermal growth factor
JP5800527B2 (ja) 2010-03-30 2015-10-28 日東電工株式会社 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
US20140207105A1 (en) 2011-08-31 2014-07-24 Perosphere, Inc. Methods for Effectively and Rapidly Desensitizing Allergic Patients
WO2013087119A1 (en) 2011-12-16 2013-06-20 Hal Allergy Holding B.V. Pharmaceutical formulations and the use thereof for the treatment of peanut allergy
CN104080465A (zh) 2012-01-13 2014-10-01 科.汉森有限公司 用于预防或治疗上呼吸道感染的鼠李糖乳杆菌和动物双歧杆菌乳亚种
CN109125283A (zh) 2013-03-14 2019-01-04 艾慕恩治疗公司 用于口服脱敏的花生制剂的制备
KR102233251B1 (ko) 2013-04-03 2021-03-26 엔-폴드 엘엘씨 신규 나노입자 조성물
US9456628B2 (en) 2013-06-13 2016-10-04 D&E Gillespie Enterpries LLC Methods and products to provide oral nutritional care to subjects with dementia
US20150343075A1 (en) 2014-06-02 2015-12-03 Aimmune Therapeutics Placebo formulations and uses thereof
EP3185900A4 (en) 2014-08-25 2018-05-02 Aimmune Therapeutics, Inc. Egg protein formulations and methods of manufacture thereof
GEAP201814459A (en) 2014-09-04 2018-09-10 Helsinn Healthcare Sa Medical treatments based on anamorelin
UA122670C2 (uk) 2014-09-08 2020-12-28 Сефалон, Інк. Спосіб лікування еозинофільної астми у пацієнта
JP2020514306A (ja) 2017-01-13 2020-05-21 アイミューン セラピューティクス，インコーポレイテッド 経口免疫療法用のナッツ粉および製剤の製造方法
FR3062797B1 (fr) * 2017-02-10 2025-03-07 Centre Hospitalier Et Univ De Clermont Ferrand Gelule a liberation gastro-intestinale destinee a etre utilisee dans une methode permettant de desensibiliser et/ou d'induire une tolerance chez un sujet allergique a l'arachide
USD866321S1 (en) 2018-07-27 2019-11-12 Aimmune Therapeutics, Inc. Box of boxes for dispensing medicine
EP3829632A4 (en) 2018-07-27 2022-05-04 Société des Produits Nestlé S.A. SYSTEMS AND METHODS FOR DELIVERING UNIT DOSES OF ORAL IMMUNOTHERAPY
USD866322S1 (en) 2018-07-27 2019-11-12 Aimmune Therapeutics, Inc. Medicine folio
USD866320S1 (en) 2018-07-27 2019-11-12 Aimmune Therapeutics, Inc. Box of boxes for dispensing medicine
US12433945B2 (en) * 2018-08-16 2025-10-07 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
AU2019401576A1 (en) 2018-12-17 2021-06-24 Société des Produits Nestlé S.A. Formulations for egg oral immunotherapy, methods of manufacture, and treatments for egg allergy
US12226448B2 (en) 2018-12-20 2025-02-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy dosing schedule for missed doses
EP3942299A4 (en) 2019-03-22 2023-06-28 Société des Produits Nestlé S.A. Systemic allergic response risk assessment in peanut oral immunotherapy
WO2020237181A1 (en) 2019-05-23 2020-11-26 Aimmune Therapeutics, Inc. Methods of treating peanut allergy by oral immunotherapy with low-dose maintenance

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509606A (ja) 2011-03-17 2014-04-21 ケンブリッジ エンタープライズ リミティッド ピーナッツアレルギーの治療
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
WO2019089978A1 (en) 2017-11-02 2019-05-09 Aimmune Therapeutics, Inc. Methods of oral immunotherapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Allergy，2014年，Vol.69，pp.834-844
Allergy，2018年，Vol.73，pp.560-568
Annals of Allergy, Asthma & Immunology，2012年，Vol.109, No.5，pp.348-352.e2
THE LANCET，2014年，Vol.383，pp.1297-1304

Also Published As

Publication number Publication date
US20230090380A1 (en) 2023-03-23
AU2020276213A1 (en) 2021-10-28
CN113966229A (zh) 2022-01-21
EP3965815A1 (en) 2022-03-16
US20200368304A1 (en) 2020-11-26
US11229673B2 (en) 2022-01-25
JP2022532547A (ja) 2022-07-15
CA3137295A1 (en) 2020-11-19
WO2020231843A1 (en) 2020-11-19
EP3965815A4 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
JP7574222B2 (ja) ピーナツアレルギー患者の生活の質を改善するための方法
Wasserman et al. Real-world experience with peanut oral immunotherapy: lessons learned from 270 patients
Johnson et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
Emslie et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial
JP7498661B2 (ja) 経口免疫療法の方法
JP7536035B2 (ja) ピーナツに対する経口免疫療法における全身性アレルギー応答リスク評価
Fattore et al. A multicenter, randomized, placebo‐controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy
US20190247333A1 (en) Method of reduction in convulsive seizure frequency
Upton et al. Oral food challenges: Special considerations
Andres et al. Behavioural changes in patients with intellectual disability treated with perampanel
Vandervorst et al. Encephalitis associated with the SARS-CoV-2 virus: a case report
Vierow et al. Cerebral networks linked to itch-related sensations induced by histamine and capsaicin
Nourbakhsh et al. Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial
WO2020237181A1 (en) Methods of treating peanut allergy by oral immunotherapy with low-dose maintenance
Sammons et al. Ethical issues of clinical trials in children
US20200054738A1 (en) Peanut oral immunotherapy with maintenance dose
Green et al. Phenotypic psychiatric characterization of children with Williams syndrome and response of those with ADHD to methylphenidate treatment
Brown-Whitehorn et al. Sustained unresponsiveness to peanut after long-term peanut epicutaneous immunotherapy
Montero et al. Family interventions in schizophrenia: an analysis of non‐adherence
HK40067853A (en) Methods for improving the quality of life of a patient with a peanut allergy
Jossan et al. Validation of the use of the ICD-10 diagnostic code for irritable bowel syndrome in the Swedish National Patient Register
You et al. Clinical experience with sesame oral immunotherapy and a quality-of-life assessment
Akiyama et al. Efficacy of perampanel for anti-N-methyl-D-aspartate receptor encephalitis: A case report
Scheffers et al. Health-Related Quality of Life and Fatigue in Children with Pompe Disease
Tronieri et al. Use of pharmacotherapy to improve weight loss in early non-responders to behavioral treatment

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230427

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240701

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240917

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241016

R150 Certificate of patent or registration of utility model

Ref document number: 7574222

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150